• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau,

New Delhi, Oct. 3 Eli Lilly has launched the registered diabetic injection Byetta (exenatide injection) in the country. The drug treats patients with type 2 diabetes in combination with two common oral diabetes medications — metformin or sulphonylureas.

“We are delighted to launch Byetta, a novel approach to treating type 2 diabetes. Exenatide is the first in a new class of anti-diabetic medicines known as incretin mimetics and is the first FDA-approved agent of this category,” said Mr Sandeep Gupta, CMD, Lilly India, in a statement from the company.

More Stories on : New Products & Services | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Big 92.7 FM tunes into Kollywood for more content

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line